Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? (Q36399875)

14 August 2017

1 reference

title

Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? (English)

1 reference

14 August 2017

0 references

congestive heart failure

1 reference

David L Vesely

1

1 reference

14 August 2017

1 March 2006

1 reference

Clinical and Experimental Pharmacology and Physiology

14 August 2017

1 reference

14 August 2017

33

1 reference

14 August 2017

3

1 reference

14 August 2017

169-176

1 reference

Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

C-type natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Analysis of peptides derived from Pro Atrial Natriuretic Peptide that circulate in man and increase in heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

The prognostic importance of different definitions of worsening renal function in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Relationship between heart failure treatment and development of worsening renal function among hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Hospital-acquired renal insufficiency: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Amelioration of postischaemic acute renal failure in conscious dogs by human atrial natriuretic peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Four peptides decrease the number of human pancreatic adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Novel therapeutic approach for cancer using four cardiovascular hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Four peptide hormones decrease the number of human breast adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Five cardiac hormones decrease the number of human small-cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Natriuretic peptides and genesis of asthma: an emerging paradigm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04344.X

10.1111/J.1440-1681.2006.04344.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16487258